Top

Published in:

Open Access 23-09-2023 | Secukinumab | Original Research

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

Authors: Jinsui Zhang, Zemin Xia, Wanjie Guo, Xiaoxiao Ren, Fang Liu, Gargi Ratnaparkhi, Amit Pagada, Subhashini Subramanian, Min Hu, Wen Chen

Published in: Dermatology and Therapy | Issue 11/2023

Abstract

Introduction

This study assessed the cost-effectiveness of secukinumab compared with other biologics (adalimumab, infliximab, ustekinumab, ixekizumab, guselkumab, and Yisaipu [etanercept biosimilar]) for moderate-to-severe plaque psoriasis from the Chinese healthcare system perspective.

Methods

A decision-tree (first year)/Markov model (subsequent years), with an annual cycle, was implemented over a lifetime horizon. The Psoriasis Area and Severity Index (PASI) response rate at week 16 was used for treatment response. Efficacy inputs were obtained from a mixed-treatment comparison conducted using data from randomized controlled trials. Other clinical inputs (adverse events, dropout, and mortality rates), utility weights, and costs were derived from published literature and local Chinese sources. Both costs and outcomes were discounted at 5% per annum. Model outcomes included quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were conducted to test the robustness of results.

Results

For patients with moderate-to-severe psoriasis, secukinumab generated the highest QALYs (12.334) against all comparators at a lifetime cost of ¥231,477. Secukinumab dominated (higher QALYs at lower costs) all other biologics except ixekizumab in this population. Compared with secukinumab, ixekizumab incurred slightly lower costs (¥228,320) but gained lesser QALYs (12.284). Thus, secukinumab was a cost-effective treatment than ixekizumab at a willingness-to-pay (WTP) threshold of ¥257,094 per QALY gained. In the one-way sensitivity analysis, base-case results were most sensitive to changes in the PASI response at 16 weeks and year 2+ dropout rates.

Conclusion

Secukinumab is the most cost-effective treatment option for patients with moderate-to-severe psoriasis compared with other commonly used biologics from the Chinese healthcare system perspective.

Available only for authorised users

Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–94. https://doi.org/10.1016/S0140-6736(14)61909-7.CrossRefPubMed

Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8:743180. https://doi.org/10.3389/fmed.2021.743180.CrossRefPubMed

Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–7. https://doi.org/10.1684/ejd.2012.1802.CrossRefPubMed

Chen K, Wang G, Jin H, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget. 2017;8(28):46381–9. https://doi.org/10.18632/oncotarget.18453.CrossRefPubMedPubMedCentral

Pan R, Zhang J. Epidemiology and treatment of psoriasis: a Chinese perspective. Psoriasis (Auckl). 2014;4:37–47. https://doi.org/10.2147/PTT.S51717.CrossRef

Bu J, Ding R, Zhou L, et al. Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol. 2022;13:880201. https://doi.org/10.3389/fimmu.2022.880201.CrossRefPubMedPubMedCentral

Gisondi P, Bellinato F, Girolomoni G, et al. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117. https://doi.org/10.3389/fphar.2020.00117.CrossRefPubMedPubMedCentral

Pariser D, Schenkel B, Carter C, et al. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Treat. 2016;27(1):19–26. https://doi.org/10.3109/09546634.2015.1044492.CrossRefPubMed

Zhong H, Yang H, Mao Z, et al. Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study. Health Qual Life Outcomes. 2021;19(1):271. https://doi.org/10.1186/s12955-021-01902-w.CrossRefPubMedPubMedCentral

10.

Chen X, Zheng L, Zhang H, et al. Disease burden and quality of life in patients with psoriasis: an internet-based questionnaire. Chin J Dermatol. 2019;52(11):791–5. https://doi.org/10.35541/cjd.20190247.CrossRef

11.

Leo Innovation Lab and The Happiness Research Institute. World Psoriasis Happiness Report 2018 [Internet]. Leo Innovation Lab and The Happiness Research Institute, Copenhagen, Denmark. https://ifpa-pso.com/resources-tools/world-psoriasis-happiness-report-2018. Accessed 17 Feb 2023.

12.

Committee of Psoriasis, Dermatology Branch, Chinese Medical Association. Guidelines for the diagnosis and treatment of psoriasis in China: 2019 concise edition#. Int J Dermatol Venereol. 2020;3(1):14–26. https://doi.org/10.1097/JD9.0000000000000074.CrossRef

13.

Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition). Chin J Dermatol. 2019;52(10):667–710. https://doi.org/10.35541/cjd.20190847.CrossRef

14.

Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologic agents in China. Chin J Dermatol. 2021;54(12):1033–47. https://doi.org/10.35541/cjd.20210643.CrossRef

15.

Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https://doi.org/10.3390/ijms20061475.CrossRefPubMedPubMedCentral

16.

Al Sawah S, Foster SA, Goldblum OM, et al. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017;20(9):982–90. https://doi.org/10.1080/13696998.2017.1345749.CrossRefPubMed

17.

Schaefer CP, Cappelleri JC, Cheng R, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol. 2015;73(4):585–93.e3. https://doi.org/10.1016/j.jaad.2015.06.049.CrossRefPubMed

18.

Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl). 2020;133(22):2665–73. https://doi.org/10.1097/CM9.0000000000001163.CrossRefPubMed

19.

Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38. https://doi.org/10.1056/NEJMoa1314258.CrossRefPubMed

20.

Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9. https://doi.org/10.1016/j.jaad.2015.05.013.CrossRefPubMed

21.

Gutknecht M, Krensel M, Augustin M. Health economic analyses of psoriasis management: a systematic literature search. Arch Dermatol Res. 2016;308(9):601–16. https://doi.org/10.1007/s00403-016-1673-4.CrossRefPubMed

22.

Zhang W, Islam N, Ma C, et al. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics. 2015;33(4):327–40. https://doi.org/10.1007/s40273-014-0244-9.CrossRefPubMed

23.

National Institute for Health and Care Excellence (NICE). Secukinumab for treating moderate to severe plaque psoriasis, Technology appraisal guidance [TA350] [Internet]. National Institute for Health and Care Excellence (NICE), UK. 2015. https://www.nice.org.uk/guidance/ta350. Accessed 17 Feb 2023.

24.

Igarashi A, Igarashi A, Graham CN, et al. Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. J Med Econ. 2019;22:7–15. https://doi.org/10.1080/13696998.2018.1532905.CrossRef

25.

D’Ausilio A, Aiello A, Daniel F, et al. PSS50 - A cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Value Health. 2015;18(7):A424. https://doi.org/10.1016/j.jval.2015.09.574.CrossRef

26.

Lee A, Gregory V, Gu Q, et al. PSS19 - Cost-effectiveness of secukinumab compared to current treatments for the treatment of moderate to severe plaque psoriasis in Canada. Value Health. 2015;18(3):A182. https://doi.org/10.1016/j.jval.2015.03.1051.CrossRef

27.

Augustin M, McBride D, Gilloteau I, et al. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018;32(12):2191–9. https://doi.org/10.1111/jdv.15047.CrossRefPubMed

28.

Klimes J, Mollon P, Graham C, et al. PSS51 - Cost-effectiveness analysis of secukinumab compared to ustekinumab in the treatment of moderate to severe plaque psoriasis in the Czech Republic. Value Health. 2015;18(7):A424. https://doi.org/10.1016/j.jval.2015.09.575.CrossRef

29.

Costa-Scharplatz M, Lang A, Gustavsson A, et al. PSS42 - Cost-effectiveness of secukinumab compared to ustekinumab In patients with psoriasis from a Swedish health care perspective. Value Health. 2015;18(7):A422. https://doi.org/10.1016/j.jval.2015.09.566.CrossRef

30.

Johansson EC, Hartz S, Kiri SH, et al. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. J Med Econ. 2018;21(8):810–20. https://doi.org/10.1080/13696998.2018.1474747.CrossRefPubMed

31.

Johansson E, Nunez M, Svedbom A, et al. Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain. Clinicoecon Outcomes Res. 2018;10:747–59. https://doi.org/10.2147/CEOR.S167727.CrossRefPubMedPubMedCentral

32.

Augustin M, Wirth D, Mahlich J, et al. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany. J Dermatolog Treat. 2022;33(2):976–82. https://doi.org/10.1080/09546634.2020.1793891.CrossRefPubMed

33.

Li G, Gu Y, Zou Q, et al. Efficacy, safety, and pharmacoeconomic analysis of adalimumab and secukinumab for moderate-to-severe plaque psoriasis: a single-center, real-world study. Dermatol Ther (Heidelb). 2022;12(9):2105–15. https://doi.org/10.1007/s13555-022-00787-x.CrossRefPubMed

34.

Zhao Y, Cai L, Liu XY, et al. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study. Chin Med J (Engl). 2021;134(11):1324–8. https://doi.org/10.1097/CM9.0000000000001510.CrossRefPubMed

35.

Yu C, Zhang J. A network meta-analysis of the efficacy of biologics in the treatment of Chinese patients with moderate to severe psoriasis. Atopic Dermatitis and Immune Skin Disease Summit Forum. Beijing: Peking University; 2022.

36.

Pan R, Wang X, Shu M, et al. Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis. Chin Med J (Engl). 2022;135(1):11–9. https://doi.org/10.1097/CM9.0000000000001817.CrossRefPubMed

37.

Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1–233, i–iv. https://doi.org/10.3310/hta10460.CrossRefPubMed

38.

Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–76. https://doi.org/10.1002/art.21978.CrossRefPubMed

39.

Armstrong A, Paul C, Puig L, et al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 ptient-years of exposure. Dermatol Ther (Heidelb). 2020;10(1):133–50. https://doi.org/10.1007/s13555-019-00340-3.CrossRefPubMed

40.

Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17. https://doi.org/10.1016/j.jaad.2016.11.041.CrossRefPubMed

41.

National Bureau of Statistics of China. China Population and Employment Statistical Yearbook-2021 [Internet]. National Bureau of Statistics of China, China Statistics Press, Beijing. 2021. https://www.yearbookchina.com/navibooklist-n3022013208-1.html. Accessed 22 Feb 2023.

42.

Ali FM, Kay R, Finlay AY, et al. Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression. Qual Life Res. 2017;26(11):3025–34. https://doi.org/10.1007/s11136-017-1607-4.CrossRefPubMedPubMedCentral

43.

Liu GG, Wu H, Li M, et al. Chinese time trade-off values for EQ-5D health states. Value Health. 2014;17(5):597–604. https://doi.org/10.1016/j.jval.2014.05.007.CrossRefPubMed

44.

Diamantopoulos A, Finckh A, Huizinga T, et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. Pharmacoeconomics. 2014;32(8):775–87. https://doi.org/10.1007/s40273-014-0165-7.CrossRefPubMedPubMedCentral

45.

Yaozhi. Drug maximum retail price (yuan) [Internet]. Yaozhi, China. 2022. https://db.yaozh.com/yaopinjiage. Accessed 22 Feb 2023.

46.

Zhu C, Chen S, Zhu Y, et al. A retrospective study of hospitalization costs, length of hospital stay and mortality of hospital-acquired sepsis. Mod Hosp. 2018;18(11):1598–601. https://doi.org/10.3969/j.issn.1671-332X.2018.11.012.CrossRef

47.

Jin W, Zhang Y, Xu Z. Prediction of malignant tumor hospitalization, hospitalization cost and average hospitalization time based on ARIMA product seasonal model. Mod Hosp. 2019;19(3):383–9. https://doi.org/10.3969/j.issn.1671-332X.2019.03.021.CrossRef

48.

Chen L, Cheng L, Zhao X. ARIMA product season model for predicting number of inpatient and hospitalized expense of malignant tumor. China Health Stat. 2017;34(4):554–7.

49.

Du Y, Nan J, Xie H, et al. Cost and effects incurred during quarantined inpatient treatment of smear and culture positive pulmonary tuberculosis. Chin J Antituberc. 2016;38(11):1000–2. https://doi.org/10.3969/j.issn.1000-6621.2016.11.021.CrossRef

50.

Xie Y, Han J, Yu W, et al. Analysis on the structure of hospitalization expenses of pulmonary tuberculosis patients in Tianjin from 2008 to 2017. Mod Prev Med. 2019;46(10):1820–4.

51.

Lu X, Wang J, Bai L. Investigation and analysis of current status of operation of infection control departments of 201 hospitals. Chin J Hosp Infect. 2017;27(14):3339–42.

52.

Xie Z, Li H. Discussion on discount rate in pharmacoeconomic evaluation for China. Chin Health Econ. 2019;38(5):74–7. https://caod.oriprobe.com/articles/56433534/Discussion_on_Discount_Rate_in_Pharmacoeconomic_Evaluation_for_China.htm. Accessed 3 Mar 2023.

53.

National Bureau of Statistics of China. Statistical Bulletin of the People's Republic of China on the 2022 National Economic and Social Development [Internet]. China Statistics Press, Beijing. 2023. http://www.stats.gov.cn/english/PressRelease/202302/t20230227_1918979.html. Accessed 3 Mar 2023.

Title: Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
Authors: Jinsui Zhang
Zemin Xia
Wanjie Guo
Xiaoxiao Ren
Fang Liu
Gargi Ratnaparkhi
Amit Pagada
Subhashini Subramanian
Min Hu
Wen Chen
Publication date: 23-09-2023
Publisher: Springer Healthcare
Keywords: Secukinumab
Vulgar Psoriasis
Plaque Psoriasis
Infliximab
Adalimumab
Ustekinumab
Etanercept
Ixekizumab
Guselkumab
Published in: Dermatology and Therapy / Issue 11/2023
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-023-01041-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2023

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis

Neurotrophin-4 and Brain-Derived Neurotrophic Factor Serum Levels in Renal Transplant Recipients with Chronic Pruritus

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Association Between Poor Sleep and Myocardial Infarction in Patients with Psoriasis: Findings from a Cross-Sectional Study with the National Psoriasis Foundation

Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database

Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage